Patents Assigned to GUBRA A/S
  • HAM15 52 ANALOGUES WITH IMPROVED AMYLIN RECEPTOR (HAMY3R) POTENCY
    Publication number: 20250129134
    Abstract: The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50?250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50?250 pM and an hAM1R-EC50?25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
    Type: Application
    Filed: October 10, 2024
    Publication date: April 24, 2025
    Applicant: GUBRA A/S
    Inventors: JENS Christian Frøslev NIELSEN, Kristoffer Tobias Gustav RIGBOLT, Esben Matzen BECH, Morten LUNDH, Paola MAGOTTI, Borja BALLRÍN-GONZÁLEZ, Søren Ljungberg PEDERSEN, Niels VRANG
  • HAManalogues with improved amylin receptor (hAMY3R) potency
    Patent number: 12139520
    Abstract: The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50?250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50?250 pM and an hAM1R-EC50?25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: November 12, 2024
    Assignee: GUBRA A/S
    Inventors: Jens Christian Frøslev Nielsen, Kristoffer Tobias Gustav Rigbolt, Esben Matzen Bech, Morten Lundh, Paola Magotti, Borja Ballarín-González, Søren Ljungberg Pedersen, Niels Vrang
  • hAM15-52 ANALOGUES WITH IMPROVED AMYLIN RECEPTOR (hAMY3R) POTENCY
    Publication number: 20240101634
    Abstract: The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50?250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50?250 pM and an hAM1R-EC50?25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 28, 2024
    Applicant: GUBRA A/S
    Inventors: Jens Christian Frøslev NIELSEN, Kristoffer Tobias, Gustav RIGBOLT, Esben Matzen BECH, Morten LUNDH, Paola MAGOTTI, Borja BALLARiN-GONZÁLEZ, Søren Ljungberg PEDERSEN, Nieis VRANG